clinical trial · NCT03655340
A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France
Swedish Orphan Biovitrum·—·completed·n = 91
Haemophilia BAlprolix
brief summary
Alprolix (rFIXFc) is a recombinant extended half-life coagulation factor product. The purpose of this non-interventional study is to describe the real-world usage and effectiveness of Alprolix in the on-demand and prophylactic treatment of haemophilia B.
started
Sep 12, 2018
primary completion
Mar 16, 2022
completion
Mar 16, 2022
last updated
Sep 19, 2024
official title
A 24-month Prospective, Non-interventional, Multicentre Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol